The FDA lifted a hold on Geron's trial of embryonic stem cells to treat spinal cord injuries. Geron hopes to begin the trial by the end of the year. The specific cell line in use for this trial is GRNOPC1 which contains cells called oligodendrocyte progenitor cells.
This is an interesting development. Geron's stock popped 17% ($80-90 million in market cap) today on the news. That speaks to the importance of a regulatory pathway for novel biologic treatments. With the value in their stock, they can fund at least part of the trial.
Any thoughts out there on how to best fund new biologic treatments through the early clinical stages?
AM
1 comment:
I would like to exchange links with your site plateletrichplasma.blogspot.com
Is this possible?
Post a Comment